Is Granules India (GRANULES) overvalued or fairly valued?

MarketChacha shows Granules India's valuation in context — a forward P/E of about 21.3, a price-to-book of about 4.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Granules India's revenue?

Granules India reported revenue of ₹5,366 Cr for FY2026, with net profit of ₹595 Cr, per official filings.

What is the share price of Granules India (GRANULES)?

Granules India last traded at ₹853.80 (-2.5% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Granules India

GRANULES · NSE · Pharma · India

₹853.80-2.5%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 10:00 AM

Snapshot

TickerGRANULES

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees4,306

HeadquartersHyderabad, India

Market cap₹21,157 Cr

P/B4.2

Volume16.07L

Websitewww.granulesindia.com

Filings tracked0

About Granules India

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters39.3%
Institutions21.0%
Public & other39.7%

64 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend11.4% → 11.1%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 6% · PAT 5%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹1,525 Cr

Next fiscal year

Rev ₹7,180 Cr · EPS 39.02

Est. earnings growth +24.7%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹432.6052-wk range₹910.00

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹21,157 Cr

Day change

-2.5%

Fwd P/E

21.3

P/B

4.2

Div yield

0.20%

Beta

0.06

Revenue (FY2026)

₹5,366 Cr

Net margin

11.1%

Revenue CAGR (3y)

+5.9%

Profit CAGR (3y)

+4.8%

Net profit (FY2026)

₹595 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about GRANULES

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹5,366 Cr	₹595 Cr	11.1%
FY2025	₹4,482 Cr	₹502 Cr	11.2%
FY2024	₹4,506 Cr	₹405 Cr	9.0%
FY2023	₹4,512 Cr	₹517 Cr	11.4%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q2	₹1,477 Cr	₹180 Cr	12.2%
2026Q1	₹1,471 Cr	₹202 Cr	13.7%
2025Q4	₹1,388 Cr	₹150 Cr	10.8%
2025Q3	₹1,297 Cr	₹131 Cr	10.1%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.